Management of Metastatic Prostate Cancer

Patients with metastatic prostate cancer have many treatment options in both the castration-sensitive and the castration-resistant settings, and new data may impact future options. Clinicians need to be educated on results of recent trials and on updates to the NCCN Guidelines for Prostate Cancer recommendations so that they can provide optimal disease management for patients with metastatic prostate cancer.

Target Audience

This educational program is designed to meet the educational needs of physicians/oncologists, nurse practitioners, nurses, physician assistants, pharmacists, and other health care professionals who manage patients with cancer.

Learning Objectives

Following this program, participants should be able to:

  • Review recent updates to the NCCN Guidelines for Prostate Cancer.
  • Describe results of recent clinical trials for patients with metastatic castration-sensitive prostate cancer.
  • Select appropriate patients with metastatic castration-resistant prostate cancer for treatment with a new targeted radiopharmaceutical therapy.
Additional information
Supporters: 

This activity is supported by educational grants from Astellas and Seagen; AstraZeneca; AVEO Pharmaceuticals, Inc. (“AVEO Oncology”); BeiGene; Coherus BioSciences; Eisai; Exact Sciences; Fresenius Kabi USA, LLC; Genentech, a member of the Roche Group; GRAIL, LLC; GSK; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Lantheus; Lilly; Novartis; NOVOCURE; Olympus Corporation of the Americas; Puma Biotechnology; and TerSera Therapeutics LLC. This activity is supported by independent educational grants from AbbVie; Daiichi Sankyo; Gilead Sciences, Inc.; and Incyte Corporation. This activity is supported by medical education grants from Exelixis, Inc., and Karyopharm Therapeutics. This project has been made possible in part by a grant from Varian Medical Systems, a Siemens Healthineers company /Global Medical Education Grant Program. This activity has been supported by an unrestricted educational grant from GE HealthCare, Pharmaceutical Diagnostics. This activity is supported by educational funding provided by Amgen. This activity is supported through an independent medical education grant from Merck & Co., Inc. This activity is supported by a grant from Pfizer Inc.

Course summary
Available credit: 
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
    • 1.00 ANCC Pharmacology Contact Hours
  • 1.00 Participation
Course opens: 
06/01/2023
Course expires: 
03/01/2024
Cost:
$0.00
Part of: 
Recorded Presentations from the NCCN 2023 Annual Conference

Archana Ajmera, MSN, ANP-BC, AOCNP
UC San Diego Moores Cancer Center

Rana R. McKay, MD
UC San Diego Moores Cancer Center

Kelly L. Stratton, MD
OU Health Stephenson Cancer Center

 

NCCN Continuing Education Disclosure Policy

It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 

Definitions  

Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers  

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Faculty Disclosures 

The faculty listed below have the following relevant financial relationships with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.

Archana Ajmera, MSN, ANP-BC, AOCNP
Astellas Pharma US, Inc.: Honoraria 
Bayer HealthCare: Honoraria
Eisai Inc.: Honoraria 
Pfizer Inc.: Honoraria

Rana R. McKay, MD
AstraZeneca Pharmaceuticals LP: Consulting Fee
AVEO Pharmaceuticals, Inc.: Consulting Fee
Bayer HealthCare: Consulting Fee; Grant/Research Support 
Bristol-Myers Squibb Company: Consulting Fee
Calithera Biosciences, Inc.: Consulting Fee 
Caris Life Sciences: Consulting Fee 
Dendreon Corporation: Consulting Fee 
Exelixis Inc.: Consulting Fee
Janssen Pharmaceutica Products, LP: Consulting Fee 
Merck & Co., Inc.: Consulting Fee
Myovant Sciences GmbH: Consulting Fee
Novartis Pharmaceuticals Corporation: Consulting Fee 
Pfizer Inc.: Consulting Fee
sanofi-aventis U.S.: Consulting Fee 
SeaGen: Consulting Fee
Sorrento Therapeutics, Inc.: Consulting Fee 
Telix Pharmaceuticals Limited: Consulting Fee 
Tempus: Consulting Fee

Kelly L. Stratton, MD
Alliance Foundation Trials: Grant/Research Support 
AstraZeneca Pharmaceuticals LP: Grant/Research Support 
Bayer HealthCare: Product/Speakers Bureau
Carden Jennings Publishing: Consulting Fee 
Cold Genesys: Grant/Research Support 
EMD Serono: Grant/Research Support
Istari Oncology, Inc.: Grant/Research Support 
Merck & Co., Inc.: Scientific Advisor
Myriad Genetic Laboratories, Inc.: Grant/Research Support 
PAREXEL International Corporation: Grant/Research Support 
Pfizer Inc.: Grant/Research Support
Propella Therapeutics, Inc.: Grant/Research Support 
Sarah Cannon: Grant/Research Support
Steba Biotech: Grant/Research Support 
TD2 Master CDA: Grant/Research Support
Theradex Oncology: Grant/Research Support 
UroGen Pharma: Grant/Research Support

NCCN Staff Disclosures

The planners listed below have the following relevant financial relationship(s) with ineligible companies to disclose.  All of the relevant financial relationships listed for these individuals have been mitigated. 

Crystal S. Denlinger, MD 
Agios, Inc.: Grant/Research Support 
Amgen Inc.: Grant/Research Support 
AstraZeneca Pharmaceuticals LP: Grant/Research Support 
BeiGene: Scientific Advisor; Grant/Research Support 
Bristol-Myers Squibb Company: Scientific Advisor; Grant/Research Support 
Eli Lilly and Company: Grant/Research Support 
Exelixis Inc.: Grant/Research Support 
Genmab: Grant/Research Support
MacroGenics: Grant/Research Support 
MedImmune Inc: Grant/Research Support 
Merck & Co., Inc.: Scientific Advisor 
sanofi-aventis U.S.: Grant/Research Support 
Taiho Pharmaceutials Co., Ltd.: Scientific Advisor 
Zymeworks: Scientific Advisor; Grant/Research Support 

Taneal Carter 
Johnson & Johnson: Equity Interest/Stock Options 

None of the other planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

image

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
NCCN designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
NCCN designates this educational activity for a maximum of 1.0 contact hour, 1.0 of which are pharmacotherapeutic contact hours.

Pharmacists
NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.10 CEUs) of continuing education credit. UAN: JA4008196-0000-23-046-H01-P

Physician Assistants 
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until March 1, 2024. PAs should only claim credit commensurate with the extent of their participation.

Available Credit

  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
    • 1.00 ANCC Pharmacology Contact Hours
  • 1.00 Participation

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing